Literature DB >> 21389322

Flow-dependent channel formation in clots by an erythrocyte-bound fibrinolytic agent.

Kathryn C Gersh1, Sergei Zaitsev, Douglas B Cines, Vladimir Muzykantov, John W Weisel.   

Abstract

Studies in animal models have shown that plasminogen activators bound to erythrocytes (RBC-PA) have an extended lifetime in the circulation and are safer than free PAs. RBC-PAs incorporate into nascent thrombi, which are focally lysed from within, an attractive thromboprophylactic option. In static systems, RBC-PAs cleave surrounding fibrin fibers, forming pores larger than the cells themselves, and move around the pore edges, enlarging them until eventual clot dissolution. We hypothesized that under flow in blood vessels, RBC-PAs form functional patent channels before clot dissolution. Here we used perfusion chambers to study clot lysis by RBC-PAs under static versus arterial and venous flow conditions. We found that flow decelerates bulk clot lysis but quickly generates patent channels filled with passing RBCs, via pore enlargement and merging in the direction of flow. Formation of such channels by RBC-PAs may help rescue ischemic tissue before bulk dissolution of potentially occlusive clots.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21389322      PMCID: PMC3100703          DOI: 10.1182/blood-2010-10-310409

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes.

Authors:  Juan-Carlos Murciano; Sandra Medinilla; Donald Eslin; Elena Atochina; Douglas B Cines; Vladimir R Muzykantov
Journal:  Nat Biotechnol       Date:  2003-07-06       Impact factor: 54.908

2.  Lysing patterns of retracted blood clots with diffusion or bulk flow transport of plasma with urokinase into clots--a magnetic resonance imaging study in vitro.

Authors:  A Blinc; D Keber; G Lahajnar; M Stegnar; A Zidansek; F Demsar
Journal:  Thromb Haemost       Date:  1992-12-07       Impact factor: 5.249

Review 3.  Perioperative stroke.

Authors:  Magdy Selim
Journal:  N Engl J Med       Date:  2007-02-15       Impact factor: 91.245

Review 4.  Drug delivery by red blood cells: vascular carriers designed by mother nature.

Authors:  Vladimir R Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2010-04       Impact factor: 6.648

5.  The spatial dynamics of fibrin clot dissolution catalyzed by erythrocyte-bound vs. free fibrinolytics.

Authors:  K C Gersh; S Zaitsev; V Muzykantov; D B Cines; J W Weisel
Journal:  J Thromb Haemost       Date:  2010-02-09       Impact factor: 5.824

Review 6.  Fibrin-selective thrombolytic therapy for acute myocardial infarction.

Authors:  D Collen
Journal:  Circulation       Date:  1996-03-01       Impact factor: 29.690

7.  Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation.

Authors:  Sergei Zaitsev; Dirk Spitzer; Juan-Carlos Murciano; Bi-Sen Ding; Samira Tliba; M Anna Kowalska; Oscar A Marcos-Contreras; Alice Kuo; Victoria Stepanova; John P Atkinson; Mortimer Poncz; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2010-04-21       Impact factor: 22.113

8.  Flow through clots determines the rate and pattern of fibrinolysis.

Authors:  A Blinc; S D Kennedy; R G Bryant; V J Marder; C W Francis
Journal:  Thromb Haemost       Date:  1994-02       Impact factor: 5.249

9.  Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator.

Authors:  Kristina Danielyan; Kumkum Ganguly; Bi-Sen Ding; Dmitriy Atochin; Sergei Zaitsev; Juan-Carlos Murciano; Paul L Huang; Scott E Kasner; Douglas B Cines; Vladimir R Muzykantov
Journal:  Circulation       Date:  2008-09-15       Impact factor: 29.690

10.  Erythrocyte-bound tissue plasminogen activator is neuroprotective in experimental traumatic brain injury.

Authors:  Sherman C Stein; Kumkum Ganguly; Caitlin M Belfield; Xiangsheng Xu; Edward W Swanson; Xiao-Han Chen; Kevin D Browne; Victoria E Johnson; Douglas H Smith; David G LeBold; Douglas B Cines; Vladimir R Muzykantov; Vladimir R Muzykhantov
Journal:  J Neurotrauma       Date:  2009-09       Impact factor: 5.269

View more
  13 in total

1.  Biocompatible coupling of therapeutic fusion proteins to human erythrocytes.

Authors:  Carlos H Villa; Daniel C Pan; Ian H Johnston; Colin F Greineder; Landis R Walsh; Elizabeth D Hood; Douglas B Cines; Mortimer Poncz; Don L Siegel; Vladimir R Muzykantov
Journal:  Blood Adv       Date:  2018-02-13

Review 2.  Drug delivery by erythrocytes: "Primum non nocere".

Authors:  Carlos H Villa; Jerard Seghatchian; Vladimir Muzykantov
Journal:  Transfus Apher Sci       Date:  2016-10-31       Impact factor: 1.764

Review 3.  Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond.

Authors:  Carlos H Villa; Douglas B Cines; Don L Siegel; Vladimir Muzykantov
Journal:  Transfus Med Rev       Date:  2016-08-17

Review 4.  Advanced drug delivery systems for antithrombotic agents.

Authors:  Colin F Greineder; Melissa D Howard; Ronald Carnemolla; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2013-06-24       Impact factor: 22.113

Review 5.  Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers.

Authors:  Patrick M Glassman; Elizabeth D Hood; Laura T Ferguson; Zongmin Zhao; Don L Siegel; Samir Mitragotri; Jacob S Brenner; Vladimir R Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2021-09-29       Impact factor: 15.470

6.  Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion.

Authors:  Jun Deng; Heng Mei; Wei Shi; Zhi-Qing Pang; Bo Zhang; Tao Guo; Hua-Fang Wang; Xin-Guo Jiang; Yu Hu
Journal:  Curr Med Sci       Date:  2018-06-22

Review 7.  Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier.

Authors:  Carlos H Villa; Daniel C Pan; Sergei Zaitsev; Douglas B Cines; Donald L Siegel; Vladimir R Muzykantov
Journal:  Ther Deliv       Date:  2015-07

Review 8.  Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems.

Authors:  Carlos H Villa; Aaron C Anselmo; Samir Mitragotri; Vladimir Muzykantov
Journal:  Adv Drug Deliv Rev       Date:  2016-03-03       Impact factor: 15.470

Review 9.  Engineered microparticles and nanoparticles for fibrinolysis.

Authors:  Dante Disharoon; David W M Marr; Keith B Neeves
Journal:  J Thromb Haemost       Date:  2019-10-07       Impact factor: 5.824

10.  S-nitrosoglutathione acts as a small molecule modulator of human fibrin clot architecture.

Authors:  Ryon M Bateman; Christopher G Ellis; Makoto Suematsu; Keith R Walley
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.